Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.

By V. Goede, K. Fischer, R. Busch, A. Engelke, B. Eichhorst, C. Wendtner, T. Chagorova, J. de la Serna, M. Dilhuydy, T. Illmer and 13 more. New England Journal of Medicine, 2014

1,465 citations recorded by the source corpus.

Subfields: Genetics, Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/edf37c33158a39905a74c7e59058cb8b7f5f57cc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. M. Hallek

Citations in the corpus

• Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. (2016, background): “CML 1/24 (4) 1 (,1) 0/11 (0) 0 (0) 1/13 (8) 1 (,1)”
• iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. (2018, methodology): “74-76 The cumulative illness rating scale has been used successfully in the setting of multicenter clinical trials to characterize patients with concomitant morbidity, 77 although other scores to identify un fi t patients are available as well.”
• New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management (2017, background): “oped anti-CD20 antibodies ofatumumab and obinutuzumab [3, 4] and in rare cases of solid cancer patients after administration of cetuximab or trastuzumab [5, 6].”
• Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015, positive): “In patients with relevant co-morbidity, who are usually older, but without TP53 deletion/mutation, the combination of chlorambucil plus an anti-CD20 antibody (rituximab, ofatumumab or obinutuzumab) prolongs progression-free survival (PFS) when compared with monotherapy and is therefore the standard ”
• Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia (2014, neutral): “Infusion-related reaction 0 0 53 (28) 6 (3)”